Menu
Chordate has nine patent families that include three pending applications, as well as 79 granted patents spread over 32 countries. The patent families deal with various aspects of our technology and are designed to provide the best possible protection for the inventions that underpin our products.
The idea of delivering neurostimulation through mechanical vibration is unique in itself, and so is the technique of using an air-filled balloon against the mucous membrane of the nose. This has made it possible to write relatively strong patents to protect the inventions. External patent experts have assessed that our patent protection is of a high standard overall.
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of Ozilia®, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.